Shares of Biotechnology company BioNTech SE jumped 3.9% today. With many investors piling into BNTX without a second thought, it may be a good idea to take a closer look at the stock. Here are some quick facts to get you started:
-
BioNTech SE has moved 20.2% over the last year, and the S&P 500 logged a change of 28.2%
-
BNTX has an average analyst rating of buy and is -11.8% away from its mean target price of $137.69 per share
-
Its trailing earnings per share (EPS) is $-2.04
-
BioNTech SE has a trailing 12 month Price to Earnings (P/E) ratio of -59.5 while the S&P 500 average is 29.3
-
Its forward earnings per share (EPS) is $-3.9 and its forward P/E ratio is -31.1
-
The company has a Price to Book (P/B) ratio of 1.52 in contrast to the S&P 500's average ratio of 4.74
-
BioNTech SE is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53
-
BNTX has reported YOY quarterly earnings growth of 22.7% and gross profit margins of 0.8%
-
The company has a free cash flow of $1.41 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
-
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vaccine ecosystem. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.
